9. Intensive care unit admission.
| Intervention/Comparison | Outcome | Illustrative comparative risks (95% CI) | Relative effect: risk ratio (95% CI) | Number of participants (studies) | Certainty of the evidence (GRADE) | Comments: overview authors' assessment of the certainty of evidence | |
| Assumed risk | Corresponding risk | ||||||
| With comparator | With intervention | ||||||
| Inhaled anticholinergics + SABA vs SABA alone for children hospitalised with asthma (Vezina 2014) | Admission to the ICU | 0 per 1000 | 0 (not estimable) | Not estimable | 210 (1) | Low | Certainty downgraded due to very serious imprecision |
| MgSO4 + SABA + Ipratropium/Placebo + SABA + Ipratropium (Knightly 2017) | HDU/ICU admission | 59 per 1000 | 87 per 1000 (47 to 165) | 1.48 (0.79 to 2.79) | 505 (1) | Very low | Certainty downgraded due to very serious imprecision and risk of bias in review (single author decided on trial inclusion) |
| Intravenous aminophylline + beta2‐agonists + systemic steroids vs placebo + beta2‐agonists + systemic steroids (Mitra 2005) | ICU admission rates | 500 per 1000 | 370 per 1000 (260 to 530) | 0.74 (0.52 to 1.06) | 163 (1) | Low | Certainty downgraded due to serious imprecision and risk of bias in review (single author reviewed each abstract) |
CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HDU: high‐dependency unit; ICU: intensive care unit; LTRA: leukotriene receptor antagonist; MgSO4: magnesium sulfate; SABA: short‐acting beta2‐agonist.